AbbVie to Acquire West’s Arizona Device Manufacturing Facility

AbbVie and West Pharmaceutical Services have announced a definitive agreement under which AbbVie will acquire a device manufacturing facility and associated intellectual property from West in Tempe, Arizona. The transaction is expected to significantly expand AbbVie’s drug delivery device manufacturing capabilities and capacity, reinforcing the company’s long-term commitment to strengthening pharmaceutical manufacturing in the United States.

As part of the deal, AbbVie plans to hire approximately 200 employees at the Tempe site and invest more than $175 million to acquire, modernize, and fully integrate the facility into its global manufacturing network. The acquisition and planned investments align with AbbVie’s broader strategy to support innovation, enhance supply chain resilience, and improve patient access to advanced therapies.

AbbVie Chairman and Chief Executive Officer Robert A. Michael said the investment reflects the company’s long-term vision for U.S.-based manufacturing. He noted that over the next decade, AbbVie intends to invest more than $10 billion in capital to support innovation and expand its manufacturing capabilities across the country. According to Michael, the Arizona facility will strengthen AbbVie’s ability to develop and deliver next-generation medicines that can have a meaningful impact on patient outcomes.

The transaction includes the transfer of the Tempe manufacturing site, which houses multiple production lines, along with 3.5 mL on-body injector technology. This technology will support the production of both current and future AbbVie medicines, particularly in the company’s immunology and neuroscience portfolios. Drug delivery devices, including on-body injectors, play an increasingly important role in enabling convenient and patient-centric administration of complex biologic therapies, especially for chronic conditions.

For AbbVie, the acquisition represents a strategic expansion of its device manufacturing footprint and a move toward greater vertical integration. By bringing device manufacturing capabilities in-house, the company aims to enhance operational efficiency, accelerate innovation, and ensure a reliable supply of critical drug delivery systems for its growing pipeline.

The acquisition will also have a notable economic impact on Arizona. AbbVie currently employs around 29,000 people across the United States, including more than 6,000 employees at its 11 U.S. manufacturing sites, and maintains operations in all 50 states and Puerto Rico. Once completed, the Tempe facility is expected to significantly expand AbbVie’s presence in Arizona, contributing to job creation and regional economic growth.

The transaction is anticipated to close in mid-2026, subject to customary closing conditions. Upon completion, the Tempe site will become an integral part of AbbVie’s global manufacturing network, supporting the company’s mission to deliver innovative medicines to patients while reinforcing domestic manufacturing capabilities.